Search clinical trials for: A/H5N1 inactivated, split-virion influenza vaccine Adjuvant

Total 236 results

Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Austria
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
GlaxoSmithKline

Completed

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

Influenza

Taiwan, Thailand
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
PATH
Institute of Vaccines and Medical Biologicals, Vietnam; Pasteur Institute,...

Completed

Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine

Influenza

Vietnam
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Butantan Institute
University of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...

Completed

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Immunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)Vaccine

Brazil
Ology Bioservices

Completed

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
University of Rochester

Completed

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza

United States
Kaiser Permanente
Seqirus

Recruiting

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Influenza | Community-acquired Pneumonia | Cardiovascular Events

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5 Adult - Chiron Study of Bird Flu Vaccine

Influenza

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Safety of 4Fluart ID Suspension for Injection in Adult Subjects

Human Influenza

Hungary
Mahidol University
Ministry of Health, Thailand; Bhumirajanagarindra Kidney Institute, Thailand

Completed

Immune Response to Influenza Vaccine in ESRD Patients

Immunology | Nephrology
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Influenza A Virus, H7N9 Subtype

United States
Sinovac Biotech Co., Ltd

Completed

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Influenza

China
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
University Hospital, Geneva

Completed

Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients

HIV Infection | Cancer | Transplant | Pediatrics | Rheumatic Disease

Switzerland
Institut National de la Santé Et de la Recherche...
MCM Vaccines B.V.

Completed

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (Transfluvac)

Immunosuppression | Renal Transplant Recipients

France
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
PATH
Centers for Disease Control and Prevention; Institut de Recherche pour le Developpement

Completed

Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa

Influenza

Senegal
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Recruiting

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Influenza, Human

Australia
National Institute of Allergy and Infectious Diseases...

Completed

H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults

Influenza

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5 Vaccine Alone or With Adjuvant in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Novavax
Instituto Mexicano del Seguro Social

Completed

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Seasonal Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Influenza

Belgium, France
University of Bergen
Haukeland University Hospital

Completed

Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen (H1N1VAC)

Healthy

Norway
National Institute of Allergy and Infectious Diseases...

Completed

H9 Priming Study in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
Oswaldo Cruz Foundation
Ministry of Health, Brazil

Completed

Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (VIP-H1N1)

HIV Infection

Brazil
Duke University
Columbia University; Centers for Disease Control and Prevention; Children's Hospital... and other collaborators

Recruiting

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

Fever | Fever After Vaccination | Seizures Fever

United States

3

Subscribe